Literature DB >> 24903723

Older men with unexplained hepatitis.

Kok Haw Jonathan Lim1, Mark Howard2, Neil Jackson1, Sumita Verma3.   

Abstract

A 59-year-old Caucasian man presented with painless jaundice for 6 weeks. He drank 70 units of alcohol per week. Examination revealed jaundice, spider angiomata and a 3 cm firm hepatomegaly. Initial bloods: bilirubin 152 µmol/L, alanine aminotransferase 1484 IU/L, alkaline phosphatase 130 IU/L, γ-glutamyl-transpeptidase 1224 IU/L and International Normalised Ratio 1.1. A standard liver screen was normal, and an abdominal ultrasound/CT scan suggested cirrhosis, confirmed by liver biopsy on day 5. Hepatitis E virus (HEV) serology on day 6 indicated acute infection. He developed severe hepatic decompensation characterised by worsening jaundice, ascites and variceal bleeding. On day 33 ribavirin 600 mg was initiated though discontinued after 2 weeks on receipt of a negative HEV RNA. At the last follow-up he had recovered, and remains abstinent from alcohol. We describe a case of autochthonously (locally) acquired HEV infection with life-threatening hepatic decompensation in the presence of undiagnosed alcohol-related cirrhosis. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24903723      PMCID: PMC4054479          DOI: 10.1136/bcr-2013-202561

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  19 in total

1.  Clinical features and predictors of outcome in acute hepatitis A and hepatitis E virus hepatitis on cirrhosis.

Authors:  Yellapu Radha Krishna; Vivek Anand Saraswat; Khaunish Das; Goel Himanshu; Surender Kumar Yachha; Rakesh Aggarwal; Gour Choudhuri
Journal:  Liver Int       Date:  2009-03       Impact factor: 5.828

Review 2.  The two faces of hepatitis E virus.

Authors:  Eyasu H Teshale; Dale J Hu; Scott D Holmberg
Journal:  Clin Infect Dis       Date:  2010-08-01       Impact factor: 9.079

3.  Influence of immunosuppressive therapy on the natural history of genotype 3 hepatitis-E virus infection after organ transplantation.

Authors:  Nassim Kamar; Florence Abravanel; Janick Selves; Cyril Garrouste; Laure Esposito; Laurence Lavayssière; Olivier Cointault; David Ribes; Isabelle Cardeau; Marie Béatrice Nogier; Jean Michel Mansuy; Fabrice Muscari; Jean Marie Peron; Jacques Izopet; Lionel Rostaing
Journal:  Transplantation       Date:  2010-02-15       Impact factor: 4.939

4.  The global burden of hepatitis E virus genotypes 1 and 2 in 2005.

Authors:  David B Rein; Gretchen A Stevens; Jordan Theaker; John S Wittenborn; Steven T Wiersma
Journal:  Hepatology       Date:  2012-04       Impact factor: 17.425

5.  Possible risk factors for the transmission of hepatitis E virus and for the severe form of hepatitis E acquired locally in Hokkaido, Japan.

Authors:  Hitoshi Mizuo; Yasuyuki Yazaki; Kenji Sugawara; Fumio Tsuda; Masaharu Takahashi; Tsutomu Nishizawa; Hiroaki Okamoto
Journal:  J Med Virol       Date:  2005-07       Impact factor: 2.327

Review 6.  Hepatitis E.

Authors:  Nassim Kamar; Richard Bendall; Florence Legrand-Abravanel; Ning-Shao Xia; Samreen Ijaz; Jacques Izopet; Harry R Dalton
Journal:  Lancet       Date:  2012-04-30       Impact factor: 79.321

7.  In vitro replication of hepatitis E virus (HEV) genomes and of an HEV replicon expressing green fluorescent protein.

Authors:  Suzanne U Emerson; Hanh Nguyen; Judith Graff; David A Stephany; Alicia Brockington; Robert H Purcell
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

Review 8.  Hepatitis E: an emerging awareness of an old disease.

Authors:  R H Purcell; S U Emerson
Journal:  J Hepatol       Date:  2008-01-02       Impact factor: 25.083

9.  Hepatitis E outbreak on cruise ship.

Authors:  Bengü Said; Samreen Ijaz; George Kafatos; Linda Booth; H Lucy Thomas; Amanda Walsh; Mary Ramsay; Dilys Morgan
Journal:  Emerg Infect Dis       Date:  2009-11       Impact factor: 6.883

10.  Hepatitis E in England and Wales.

Authors:  Hannah C Lewis; Sophie Boisson; Samreen Ijaz; Kirsten Hewitt; Siew Lin Ngui; Elizabeth Boxall; Chong Gee Teo; Dilys Morgan
Journal:  Emerg Infect Dis       Date:  2008-01       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.